U.S. markets open in 4 hours 11 minutes

Quanterix Corporation (QTRX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
63.61+1.67 (+2.70%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close61.94
Open62.14
Bid0.00 x 1200
Ask0.00 x 800
Day's Range61.42 - 64.55
52 Week Range22.49 - 92.57
Volume172,735
Avg. Volume448,176
Market Cap2.307B
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-1.07
Earnings DateMar 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est89.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Quanterix’ Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva Samples
    Business Wire

    Quanterix’ Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva Samples

    Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa® technology has been used in research studies to detect the SARS-CoV-2 virus in serum/plasma, dried blood microsamples (DBS) and saliva samples obtained from polymerase chain reaction (PCR)+ COVID-19 patients. Published in Nature Communications, the research study of these technologies offers further evidence that non-invasive antigen detection in blood or saliva samples, including from asymptomatic and pre-symptomatic individuals, can serve as an important complement to testing of nasal and nasopharyngeal (NP) swab samples. In addition to the benefits of detecting COVID-19 during the pre-symptomatic window when transmissibility is known to be highest, measuring viral load in blood may be particularly relevant in the context of clinical studies, as an indicator of disease severity or progression, and potentially of therapeutic efficacy.

  • Quanterix’ Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson’s & Alzheimer’s Disease (AD/PDTM 2021)
    Business Wire

    Quanterix’ Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson’s & Alzheimer’s Disease (AD/PDTM 2021)

    Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology and various blood-based neurology biomarker assays were used by leading research teams to power 30 total oral and poster presentations at this year’s AD/PD 2021. The research efforts further underscore the vast utility of several blood-based biomarkers offered through Quanterix’ Neurology kits, including phosphorylated tau at threonine 181 (p-tau181), phosphorylated tau at threonine 231 (p-tau231), glial fibrillary acidic protein (GFAP) and Neurofilament light chain (NfL). Notable findings showcased at the conference validate the potential of these markers as pre-screening tools prior to costly PET scans, as secondary endpoints of drug efficacy, and as important tools for the recruitment and disease stratification of pre-symptomatic patients into clinical trials through non-invasive methods.

  • Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates

    Quanterix Corporation (QTRX) delivered earnings and revenue surprises of -3.33% and 3.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?